Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML

Despite significant advancements in developing selective FMS-like tyrosine kinase 3 (FLT3) inhibitors, resistance to treatment is common even on continued therapy. Acquisition of on-target mutations or adaptation to MAPK, JAK2, and ABL signaling pathways drive treatment failure and disease relapse....

Descripción completa

Detalles Bibliográficos
Autores principales: Azhar, Mohammad, Kincaid, Zachary, Kesarwani, Meenu, Menke, Jacob, Schwieterman, Joshua, Ansari, Sekhu, Reaves, Angela, Ahmed, Arhama, Shehzad, Rammsha, Khan, Areeba, Syed, Nuha, Amir, Noor, Wunderlich, Mark, Latif, Tahir, Seibel, William, Azam, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125913/
https://www.ncbi.nlm.nih.gov/pubmed/36044389
http://dx.doi.org/10.1182/bloodadvances.2022007486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125913/
https://www.ncbi.nlm.nih.gov/pubmed/36044389
http://dx.doi.org/10.1182/bloodadvances.2022007486

Ejemplares similares